Generation of kinins during preparation and storage of whole blood-derived platelet concentrates

Transfusion

Volumn 47, Issue 3, 2007, Pages 410-420

  Moreau, Marie Eve ^b   Thibault, Louis ^b   Désormeaux, Anik ^b   Chagnon, Miguel ^b   Lemieux, Réal ^b   Robillard, Pierre ^b   Marceau, François ^b   Colman, Robert W ^b   Lepage, Yves ^b   Rivard, Georges Étienne ^b   Adam, Albert ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BRADYKININ[1-8]; KININ; THROMBOCYTE CONCENTRATE;

ADULT; AGED; ARTICLE; ENZYME IMMUNOASSAY; FEMALE; FILTRATION; HUMAN; IMMUNOREACTIVITY; MALE; MOLECULAR WEIGHT; NORMAL HUMAN; PHYSICAL CHEMISTRY; PLASMA; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN HYDROLYSIS; THROMBOCYTE PRESERVATION; TIME;

AGED; ALGORITHMS; BLOOD PLATELETS; BLOOD PRESERVATION; BLOOD SPECIMEN COLLECTION; CELLS, CULTURED; FEMALE; HEMOFILTRATION; HUMANS; IMMUNOASSAY; KININS; MALE; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A;

EID: 33847043842     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2007.01097.x     Document Type: Article

References (49)

1. Snyder EL. Transfusion reactions. In: Hoffman R, editor. Hematology: basic principles and practice. Churchill Livingstone Inc.; 1995. p. 2045-53.
2. Chu RW. Leukocytes in blood transfusion: adverse effects and their prevention. Hong Kong Med J 1999;5:280-4.
3. Stack G, Snyder EL. Cytokine generation in stored platelet concentrates. Transfusion 1994;34:20-5.
4. Aye MT, Palmer DS, Giulivi A, Hashemi S. Effect of filtration of platelet concentrates on the accumulation of cytokines and platelet release factors during storage. Transfusion 1995;35:117-24.
5. Wadhwa M, Seghatchian MJ, Lubenko A, et al. Cytokine levels in platelet concentrates: quantitation by bioassays and immunoassays. Br J Haematol 1996;93:225-34.
6. Federowicz I, Barrett BB, Andersen JW, et al. Characterization of reactions after transfusion of cellular blood components that are white cell reduced before storage. Transfusion 1996;36:21-8.
7. Petranyi GG, Reti M, Harsanyi V, Szabo J. Immunologic consequences of blood transfusion and their clinical manifestations. Int Arch Allergy Immunol 1997;114:303-15.
8. Zoon KC, Jacobson ED, Woodcock J. Hypotension and bedside leukocyte reduction filters. Int J Trauma Nurs 1999;5:121-2.
9. Cyr M, Hume HA, Champagne M, et al. Anomaly of the des-Arg9-bradykinin metabolism associated with severe hypotensive reactions during blood transfusions: a preliminary study. Transfusion 1999;39:1084-8.
10. Cyr M, Eastlund T, Blais C Jr, et al. Bradykinin metabolism and hypotensive transfusion reactions. Transfusion 2001;41:136-50.
11. Hume HA, Adam A. Hypotensive transfusion reactions. In: Popovsky MA, editor. Transfusion reactions. Bethesda: American; 2001. p. 213-33.
12. Arnold DM, Molinaro G, Warkentin TE, et al. Hypotensive transfusion reactions can occur with blood products that are leukoreduced before storage. Transfusion 2004;44:1361-6.
13. Decarie A, Raymond P, Gervais N, et al. Serum interspecies differences in metabolic pathways of bradykinin and [des-Arg9]BK: influence of enalaprilat. Am J Physiol 1996;271(4 Pt 2):H1340-7.
14. Cyr M, Lepage Y, Blais C Jr, et al. Bradykinin and des-Arg (9)-bradykinin metabolic pathways and kinetics of activation of human plasma. Am J Physiol Heart Circ Physiol 2001;281:H275-83.
15. Moreau ME, Garbacki N, Molinaro G, et al. The kallikreinkinin system: current and future pharmacological targets. J Pharmacol Sci 2005;99:6-38.
16. Leeb-Lundberg LM, Marceau F, Muller-Esterl W, et al. International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev 2005;57:27-77.
17. Hild M, Soderstrom T, Egberg N, Lundahl J. Kinetics of bradykinin levels during and after leucocyte filtration of platelet concentrates. Vox Sang 1998;75:18-25.
18. Takahashi TA, Abe H, Hosoda M, et al. Bradykinin generation during filtration of platelet concentrates with a white cell-reduction filter. Transfusion 1995;35:967.
19. Takahashi TA, Abe H, Fujihara M, et al. Quality of platelet components: the role of suspension medium and leukocyte depletion. Transfus Clin Biol 1994;1:481-7.
20. Shiba M, Tadokoro K, Sawanobori M, et al. Activation of the contact system by filtration of platelet concentrates with a negatively charged white cell-removal filter and measurement of venous blood bradykinin level in patients who received filtered platelets. Transfusion 1997;37:457-62.
21. Takahashi TA, Hosoda M, Abe H, Sekiguchi S. Bradykinin formation in a platelet concentrate filtered with a leukocyte-removal filter made of nonwoven polyester fibers with a negatively charged surface. Transfusion 1994;34(Suppl):S22.
22. Davenport RD, Penezina OP. Cleavage of high molecular weight kininogen induced by filtration of platelet concentrates. Transfusion 1997;37(Suppl):104S.
23. Molinaro G, Adam A, Lepage Y, et al. Hypotensive reaction during staphylococcal protein A column therapy in a patient with anomalous degradation of bradykinin and Des-Arg9-bradykinin after contact activation. Transfusion 2002;42:1458-65.
24. Decarie A, Drapeau G, Closset J, et al. Development of digoxigenin-labeled peptide: application to chemiluminoenzyme immunoassay of bradykinin in inflamed tissues. Peptides 1994;15:511-8.
25. Raymond P, Drapeau G, Raut R, et al. Quantification of des-Arg9-bradykinin using a chemiluminescence enzyme immunoassay: application to its kinetic profile during plasma activation. J Immunol Methods 1995;180:247-57.
26. Blais C Jr, Lapointe N, Rouleau JL, et al. Effects of the vasopeptidase inhibitor omapatrilat on cardiac endogenous kinins in rats with acute myocardial infarction. Peptides 2001;22:953-62.
27. Blais C Jr, Marceau F, Rouleau JL, Adam A. The kallikreinkininogen-kinin system: lessons from the quantification of endogenous kinins. Peptides 2000;21:1903-40.
28. Guimaraes JA, Pierce JV, Hial V, Pisano JJ. Methionyl-lysylbradykinin: the kinin released by pepsin from human kininogens. Adv Exp Med Biol 1976;70:265-9.
29. Molinaro G, Cugno M, Perez M, et al. Angiotensin-converting enzyme inhibitor-associated angioedema is characterized by a slower degradation of des-arginine9-bradykinin. J Pharmacol Exp Ther 2002;303:232-7.
30. Adam A, Perez M, Molinaro G, et al. Angiotensin I converting enzyme inhibitor (ACEi) associated angioedema (AE) is characterized by an anomaly of the metabolism of endogenous plasma des-Arg9-bradykinin [abstract]. Circulation 2001;104(Suppl II):II-450.
31. Blais C Jr, Marc-Aurele J, Simmons WH, et al. Des-Arg9-bradykinin metabolism in patients who presented hypersensitivity reactions during hemodialysis: role of serum ACE and aminopeptidase P. Peptides 1999;20:421-30.
32. Blais C Jr, Rouleau JL, Brown NJ, et al. Serum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitor-associated angioedema. Immunopharmacology 1999;43:293-302.
33. Sabourin T, Bastien L, Bachvarov DR, Marceau F. Agonist-induced translocation of the kinin B(1) receptor to caveolae-related rafts. Mol Pharmacol 2002;61:546-53.
34. Houle S, Larrivee JF, Bachvarova M, et al. Antagonist-induced intracellular sequestration of rabbit bradykinin B(2) receptor. Hypertension 2000;35:1319-25.
35. Bachvarov DR, Saint-Jacques E, Larrivee JF, et al. Cloning and pharmacological characterization of the rabbit bradykinin B2 receptor. J Pharmacol Exp Ther 1995;275:1623-30.
36. Molinaro G, Carmona AK, Juliano MA, et al. Human recombinant membrane-bound aminopeptidase P. production of a soluble form and characterization using novel, internally quenched fluorescent substrates. Biochem J 2005;385 (2):389-97.
37. Skidgel RA. Human carboxypeptidase N: lysine carboxypeptidase. Methods Enzymol 1995;248:653-63.
38. Miller RG Jr. Beyond ANOVA: basics of applied statistics. New York: Wiley; 1986.
39. Neter J, Wasserman W, Kutner MH. Applied linear statistical models. 4th ed. Chicago: Irwin; 1996.
40. Fried MR, Eastlund T, Christie B, et al. Hypotensive reactions to white cell-reduced plasma in a patient undergoing angiotensin-converting enzyme inhibitor therapy. Transfusion 1996;36:900-3.
41. Adam A, Cugno M, Molinaro G, et al. Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors. Lancet 2002;359:2088-9.
42. Colman RW, Schmaier AH. Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood 1997;90:3819-43.
43. Molinaro G, Gervais N, Adam A. Biochemical basis of angioedema associated with recombinant tissue plasminogen activator treatment: an in vitro experimental approach. Stroke 2002;33:1712-6.
44. Ewald GA, Eisenberg PR. Plasmin-mediated activation of contact system in response to pharmacological thrombolysis. Circulation 1995;91:28-36.
45. Kleniewski J, Blankenship DT, Cardin AD, Donaldson V. Mechanism of enhanced kinin release from high molecular weight kininogen by plasma kallikrein after its exposure to plasmin. J Lab Clin Med 1992;120:129-39.
46. Dewald G, Bork K. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun 2006;343:1286-9.
47. Wiggins RC. Kinin release from high molecular weight kininogen by the action of Hageman factor in the absence of kallikrein. J Biol Chem 1983;258:8963-70.
48. Schmaier AH, Schutsky D, Farber A, et al. Determination of the bifunctional properties of high molecular weight kininogen by studies with monoclonal antibodies directed to each of its chains. J Biol Chem 1987;262:1405-11.
49. Colman RW, Scott CF. Hypotensive reactions during transfusion: is bradykinin the culprit? Transfusion 1999;39:107-9.